Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5006280 | 1.00 | MAPT (0.46) | MAPTALDH1A1KMT2APOLBMEN1 | |
| SCHEMBL18299213 | 0.90 | MAPT (0.41) | MAPTALDH1A1KMT2APOLBMEN1 | |
| SCHEMBL24397740 | 0.88 | PPM1B (0.42) | MAPTALDH1A1KMT2APOLBMEN1 | |
| SCHEMBL17374412 | 0.86 | ALDH1A1 (0.40) | MAPTALDH1A1KMT2APOLBMEN1 | |
| SCHEMBL17374415 | 0.86 | ALDH1A1 (0.40) | MAPTALDH1A1KMT2APOLBMEN1 | |
| SCHEMBL4221 | 0.82 | — | — | |
| SCHEMBL237380 | 0.82 | MAPT (0.60) | MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL2375356 | 0.82 | MAPT (0.60) | MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL8891623 | 0.82 | MAPT (0.60) | MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL21072791 | 0.82 | SMN1; SMN2 (0.44) | MAPTALDH1A1KMT2APOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12552804-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2026-02-17 | — | — | US | disclosed |
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20250084041-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | THE UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2025-03-13 | — | — | US | disclosed |
| EP-4457217-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | Curza Global LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| CN-118786118-A | Antimicrobial compounds and methods | 库扎环球有限责任公司 | 2024-10-15 | — | — | CN | disclosed |
| US-20240287086-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2024-08-29 | — | — | US | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-7452893-B2 | 4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists | MERCK & CO., INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452893-B2 | 4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists | MERCK & CO., INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20070037829-A1 | e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients | MERCK & CO., INC. (US) | 2007-02-15 | — | — | US | disclosed |
| EP-1656379-B1 | 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1656379-A1 | 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050054658-A1 | 4-Cycloalkylaminopyrazolo pyrimidine NMDA/NR2B antagonists | THOMPSON WAYNE (US) | 2005-03-10 | — | — | US | disclosed |
| WO-2005019222-A1 | 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005019221-A1 | 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005019221-A1 | 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005019222-A1 | 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MAPT 2459/4885ALDH1A1 2776/4885KMT2A 445/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MAPT 2459/4885ALDH1A1 2776/4885KMT2A 445/4885 |
| US-20240287086-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | MAPT 4197/4885ALDH1A1 879/4885KMT2A 1324/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MAPT 2459/4885ALDH1A1 2776/4885KMT2A 445/4885 |
| US-20070037829-A1 | e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients | GRIN2B, GRIN3A, GRIN2A | MAPT 56/4885ALDH1A1 636/4885KMT2A 1538/4885 |
| US-12552804-B2 | Tricyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | MAPT 4769/4885ALDH1A1 478/4885KMT2A 2514/4885 |
| US-20250084041-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | MPO, NISCH, RPN2 | MAPT 4367/4885ALDH1A1 3752/4885KMT2A 4067/4885 |
| US-20050054658-A1 | 4-Cycloalkylaminopyrazolo pyrimidine NMDA/NR2B antagonists | GRIN2B, GRIN1, GRIN2A | MAPT 473/4885ALDH1A1 638/4885KMT2A 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.